SOUTH SAN FRANCISCO, Calif., March 30 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today announced that each of its four submitted abstracts have been accepted for presentation at the 2006 American Association for Cancer Research (AACR) Annual Meeting which will take place in Washington, DC, April 2 to 5. The four abstracts to be presented by Cell Genesys scientists are as follows:
-- Humoral immune response induced to filamin B in patients with metastatic hormone-refractory prostate cancer (HRPC) treated with a GM-CSF-transduced allogeneic prostate cancer vaccine (GVAX(R)). (To be presented in a poster discussion on Monday, April 3, 1:00 - 5:00 p.m. EDT) (Abstract ID: 2894) -- Local secretion of anti-CTLA-4 antibody from a GM-CSF-secreting tumor cell vaccine enhances vaccine efficacy (To be presented in mini-symposia on Sunday, April 2, 3:25 - 3:40 p.m. EDT) (Abstract ID: 1520) -- EGFR inhibitors decrease the potency of GM-CSF-secreting tumor cell vaccines by inhibiting T-cell activation. (To be presented in a poster discussion on Sunday, April 2, 1:00 - 5:00 p.m. EDT) (Abstract ID: 1398) -- An armed oncolytic vector (OV1203) expressing E. coli purine nucleoside phosphorylase (PNP) combined with Fludara(TM) shows increased efficacy. (To be presented in mini-symposia on Tuesday, April 4, 11:40 - 11:55 a.m. EDT) (Abstract ID: 4022)
Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(R) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapy for pancreatic cancer and leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company’s website at www.cellgenesys.com.
Statements made herein about the company, other than statements of historical fact, including statements about the company’s progress, results and timing of clinical trials and preclinical programs and the nature of product pipelines are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials and research and development programs, the regulatory approval process for clinical trials, competitive technologies and products, patents, continuation of corporate partnerships and the need for additional financings. For information about these and other risks which may affect Cell Genesys, please see the company’s Annual Report on Form 10-K for the year ended December 31, 2005 filed on March 13, 2006 as well as Cell Genesys’ reports on Form 10-Q and 8-K and other reports filed from time to time with the Securities and Exchange Commission. The company assumes no obligation to update the forward-looking information in this press release.
Contact: Ina Cu
Investor Relations 650-266-3200
Cell Genesys, Inc.
CONTACT: Ina Cu, Investor Relations of Cell Genesys, +1-650-266-3200
Web site: http://www.cellgenesys.com/
